lamdis

How to appeal a Rinvoq denial

Reviewed · 15 sources

The short answer

Most Rinvoq denials come from step therapy. Its own FDA label limits several uses to people who already tried a TNF blocker such as Humira, and plans enforce that. Get the plan's written criteria, then send records of each prior drug with dates, doses and results. If you could not take a TNF blocker, your doctor's letter should say why.

The appeal at a glance
  1. StartThe denial letterFind what was denied, the reason, and the deadline to appeal.
  2. Step 1Appeal to your planMost plans give you 60 to 180 days to ask. The plan reviews its own decision.
  3. Step 2Go outside the planIf it says no again, someone outside the plan can decide: an independent reviewer, a hearing, or a federal office.

Can’t wait? If waiting could seriously harm your health, ask for a fast appeal. Most plans must decide within 72 hours.

What Rinvoq is approved for

Rinvoq (upadacitinib) is a JAK inhibitor pill. Its FDA label lists uses including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, ankylosing spondylitis and atopic dermatitis (eczema). For several of those, the label itself says the patient should have had an inadequate response or intolerance to one or more TNF blockers. For eczema, it is for disease not adequately controlled with other systemic drug products, including biologics.

Rinvoq carries a boxed warning about serious infections, cancer, heart events and blood clots, which is one reason plans review it closely.

Why plans deny Rinvoq

No documented TNF blocker trial. One insurer's national policy asks, for several conditions, that the patient had a 3-month trial of at least one TNF inhibitor or could not tolerate one. Older drugs such as methotrexate do not count toward that step.

Eczema criteria not met. The same policy asks for a 4-month trial of at least one systemic therapy, such as Dupixent or methotrexate, and an allergist, immunologist or dermatologist as prescriber.

A preferred product comes first. In that insurer's national formulary program, Rinvoq is a non-preferred product for rheumatology and bowel conditions, directed to a preferred product such as an adalimumab biosimilar first.

The renewal lacked proof. Renewals ask for a beneficial response by an objective measure or symptom improvement since starting.

Reading the denial

Job-based plans must name the specific plan provision behind a denial, and you can ask for a free copy of the criteria. "Criteria not met" means the plan wanted more medical proof; see prior authorization denials. "Step therapy" or "try a preferred product first" means the plan wants another drug tried; see step therapy denials. "Non-formulary" means Rinvoq is not on the drug list, which calls for a formulary exception. Check your plan's drug list to see what it prefers.

What your doctor's letter should document

Ask for a letter of medical necessity that answers each criterion, in order, with dated records:

  • The diagnosis and its diagnosis code, with disease activity scores the criteria mention.
  • Each TNF blocker or systemic drug tried: name, dose, start and stop dates, and what happened.
  • If you never took a TNF blocker, the medical reason it was unsafe or inadvisable for you.
  • The specialist's role.
  • For renewals, measurements from before Rinvoq and now.

Ask the plan for the written criteria it used. Job-based plans must name the specific plan provision behind a denial and give you a free copy of any criteria they relied on. File the internal appeal within 180 days of the denial.

If Rinvoq is not on the drug list, ask for a formulary exception instead of, or alongside, the appeal. Your doctor generally confirms that covered drugs have not worked, will not work as well, or are likely to cause harm. Individual and small-group plans must decide a standard request within 72 hours and an expedited one within 24 hours, and a denial can go to an independent reviewer. See formulary exception letters.

If the plan upholds a denial that turned on medical judgment, you can ask for external review within 4 months of the final decision. Your insurer has to accept the reviewer’s decision.

Medicare, Medicaid and manufacturer help

With a Medicare drug plan, ask for a coverage determination or exception. Your prescriber must provide a statement explaining the medical reason. The plan must decide within 72 hours, or 24 hours if expedited, and Part D exceptions can also cover step therapy and dose limits. You have 65 days to appeal a denial. See Part D appeals.

State Medicaid programs may require prior authorization for any covered drug. See Medicaid appeals.

AbbVie runs Rinvoq Complete, which helps with possible ways to save and insurance coverage questions.

Questions people ask

Do I have to try Humira before Rinvoq?

For several uses, yes or something like it. The FDA label limits rheumatoid arthritis and other uses to people who had an inadequate response or intolerance to one or more TNF blockers, and plans ask for proof such as a 3-month trial.

What counts as proof of a prior trial?

One policy accepts chart notes, prescription claims records and prescription receipts. Include dates and doses.

Insurance stopped covering Rinvoq after I'd been on it. What can I do?

First find out why: a lapsed prior authorization, a renewal that asked for proof the drug is working, or a drug-list change. Ask your doctor to resubmit with current records. In individual and small-group plans, being in the middle of a course of treatment on a non-formulary drug qualifies for a 24-hour expedited exception. Medicare drug plans must offer a temporary supply in the first 90 days under a new plan, and that process also covers current enrollees affected by formulary changes.

What if my Rinvoq appeal is denied?

If the denial turned on medical judgment, you can ask for external review by an independent reviewer within 4 months of the plan's final decision. A denied formulary exception in an individual or small-group plan can also go to independent review. With Medicare Part D, if the plan upholds its denial you have 60 days to ask a Part D Independent Review Entity to reconsider; see Part D appeals.

Sources

  1. National Library of Medicine (DailyMed): RINVOQ/RINVOQ LQ (upadacitinib) prescribing information (DailyMed)RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
  2. Cigna Healthcare: Inflammatory Conditions – Rinvoq/Rinvoq LQ Prior Authorization Policy (Cigna National Formulary, review date 02/11/2026)Patient has had a 3-month trial of at least ONE tumor necrosis factor inhibitor
  3. Cigna Healthcare: Inflammatory Conditions Preferred Specialty Management Policy for National Preferred and Basic Formularies (Cigna, review date 07/29/2026)this program requires trial(s) of the Preferred Product(s) according to the table below when clinically appropriate, prior to the approval of the Non-Preferred Products
  4. eCFR (Office of the Federal Register): 29 CFR 2560.503-1 -- Claims procedureReference to the specific plan provisions on which the determination is based
  5. HealthCare.gov: Getting prescription medicationsVisit your insurer’s website to review a list of prescriptions your plan covers
  6. HealthCare.gov: Internal appealsYou must file your internal appeal within 180 days (6 months) of receiving notice that your claim was denied.
  7. eCFR (Office of the Federal Register): 45 CFR 156.122 -- Prescription drug benefitsA health plan must make its determination on a standard exception and notify the enrollee or the enrollee's designee and the prescribing physician (or other prescriber, as appropriate) of its coverage determination no later than 72 hours following receipt of the request.
  8. HealthCare.gov: External ReviewYou must file a written request for an external review within 4 months after the date you receive a notice or final determination from your insurer that your claim has been denied.
  9. Medicare.gov: Appeals in a Medicare drug planIf you're asking for an exception, your prescriber must provide a statement explaining the medical reason why the exception should be approved.
  10. eCFR (Office of the Federal Register): 42 CFR 423.568 -- Standard timeframe and notice requirements for coverage determinationsbut no later than 72 hours after receipt of the physician's or other prescriber's supporting statement
  11. eCFR (Office of the Federal Register): 42 CFR 423.572 -- Timeframes and notice requirements for expedited coverage determinationsbut no later than 24 hours after receipt of the physician's or other prescriber's supporting statement
  12. eCFR (Office of the Federal Register): 42 CFR 423.578 -- Exceptions processAn exception to a plan's coverage policy that causes a Part D prescription drug not to be covered because of cost utilization tools, such as a requirement for step therapy, dosage limitations, or therapeutic substitution.
  13. Legal Information Institute, Cornell Law School: 42 U.S. Code § 1396r-8 - Payment for covered outpatient drugsA State may subject to prior authorization any covered outpatient drug
  14. AbbVie: RINVOQ CompleteWith RINVOQ Complete, you’ll get help finding potential ways to save on your prescription, answers to your health insurance coverage questions
  15. eCFR (Office of the Federal Register): 42 CFR 423.120 -- Access to covered Part D drugsEnsure access to a temporary supply of drugs within the first 90 days of coverage under a new plan.

This page is general information about appeal rules in the United States. It is not legal or medical advice. Rules can change, and your plan’s documents and your denial letter control the dates that apply to you.